The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aceso Company Pte. Ltd.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Singapore-based Aceso Company Pte. Ltd., a former promoter of HealthCare Global Enterprises (HCG), sold 7.19 crore equity shares (~51.59% of total share capital) on May 30, 2025 through an off-market deal. Before the sale, Aceso held 8.41 crore shares (60.35%) in HCG; after the sale, its holding dropped to 1.22 crore shares (~8.76%). The transaction was executed under a share purchase agreement dated February 23, 2025 involving Hector Asia II Pte. Ltd. and KIA EBT II Scheme I. As a result of the sale, Aceso will be reclassified from a 'promoter' to a 'public' shareholder of the company.
This is a major promoter exit — HCG loses its largest controlling shareholder and the promoter group stake falls well below 50%. The change in control could shift strategic direction, governance, and majority ownership to the new buyers (Hector Asia / KIA), which may materially affect stock price and investor sentiment in the short term.